Literature DB >> 24722207

Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice.

Fumiaki Saito1, Motoi Kanagawa2, Miki Ikeda3, Hiroki Hagiwara4, Toshihiro Masaki5, Hidehiko Ohkuma3, Yuki Katanosaka6, Teruo Shimizu7, Masahiro Sonoo3, Tatsushi Toda2, Kiichiro Matsumura3.   

Abstract

Several types of muscular dystrophy are caused by defective linkage between α-dystroglycan (α-DG) and laminin. Among these, dystroglycanopathy, including Fukuyama-type congenital muscular dystrophy (FCMD), results from abnormal glycosylation of α-DG. Recent studies have shown that like-acetylglucosaminyltransferase (LARGE) strongly enhances the laminin-binding activity of α-DG. Therefore, restoration of the α-DG-laminin linkage by LARGE is considered one of the most promising possible therapies for muscular dystrophy. In this study, we generated transgenic mice that overexpress LARGE (LARGE Tg) and crossed them with dy(2J) mice and fukutin conditional knockout mice, a model for laminin α2-deficient congenital muscular dystrophy (MDC1A) and FCMD, respectively. Remarkably, in both the strains, the transgenic overexpression of LARGE resulted in an aggravation of muscular dystrophy. Using morphometric analyses, we found that the deterioration of muscle pathology was caused by suppression of muscle regeneration. Overexpression of LARGE in C2C12 cells further demonstrated defects in myotube formation. Interestingly, a decreased expression of insulin-like growth factor 1 (IGF-1) was identified in both LARGE Tg mice and LARGE-overexpressing C2C12 myotubes. Supplementing the C2C12 cells with IGF-1 restored the defective myotube formation. Taken together, our findings indicate that the overexpression of LARGE aggravates muscular dystrophy by suppressing the muscle regeneration and this adverse effect is mediated via reduced expression of IGF-1.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722207     DOI: 10.1093/hmg/ddu168

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.

Authors:  Evelyne Gicquel; Natacha Maizonnier; Steven J Foltz; William J Martin; Nathalie Bourg; Fedor Svinartchouk; Karine Charton; Aaron M Beedle; Isabelle Richard
Journal:  Hum Mol Genet       Date:  2017-05-15       Impact factor: 6.150

2.  212th ENMC International Workshop: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015.

Authors:  M Saunier; C G Bönnemann; M Durbeej; V Allamand
Journal:  Neuromuscul Disord       Date:  2016-02-15       Impact factor: 4.296

Review 3.  Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane.

Authors:  Takako Yoshida-Moriguchi; Kevin P Campbell
Journal:  Glycobiology       Date:  2015-04-16       Impact factor: 4.313

4.  Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.

Authors:  Yoshihisa Ohtsuka; Motoi Kanagawa; Chih-Chieh Yu; Chiyomi Ito; Tomoko Chiyo; Kazuhiro Kobayashi; Takashi Okada; Shin'ichi Takeda; Tatsushi Toda
Journal:  Sci Rep       Date:  2015-02-09       Impact factor: 4.379

5.  Postnatal Gene Therapy Improves Spatial Learning Despite the Presence of Neuronal Ectopia in a Model of Neuronal Migration Disorder.

Authors:  Huaiyu Hu; Yu Liu; Kevin Bampoe; Yonglin He; Miao Yu
Journal:  Genes (Basel)       Date:  2016-11-29       Impact factor: 4.096

6.  A new model of skeletal muscle atrophy induced by immobilization using a hook-and-loop fastener in mice.

Authors:  Masahiro Aihara; Noboru Hirose; Wakana Katsuta; Fumiaki Saito; Hitoshi Maruyama; Hiroki Hagiwara
Journal:  J Phys Ther Sci       Date:  2017-10-21

Review 7.  Genetic Engineering of Dystroglycan in Animal Models of Muscular Dystrophy.

Authors:  Francesca Sciandra; Maria Giulia Bigotti; Bruno Giardina; Manuela Bozzi; Andrea Brancaccio
Journal:  Biomed Res Int       Date:  2015-08-24       Impact factor: 3.411

8.  Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?

Authors:  J C W Hildyard; E Lacey; H Booler; M Hopkinson; D J Wells; S C Brown
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

9.  Changes in oxidative stress severity and antioxidant potential during muscle atrophy and reloading in mice.

Authors:  Wakana Katsuta; Masahiro Aihara; Noboru Hirose; Fumiaki Saito; Hiroki Hagiwara
Journal:  J Phys Ther Sci       Date:  2018-01-27

Review 10.  Treating pediatric neuromuscular disorders: The future is now.

Authors:  James J Dowling; Hernan D Gonorazky; Ronald D Cohn; Craig Campbell
Journal:  Am J Med Genet A       Date:  2017-09-10       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.